The greatest simultaneous decline of cyclin D1, CDK4 kinase, and cyclin D3 and CDK6 kinase was observed after treatment of melanoma cell with the combination of inhibitors: mTOR—everolimus, with ERK1/2 inhibitor—U126 or B-RAF-GDC-0879 (Fig. 3a, b). This evidence concerns the gene MAPK3 and melanoma.